No Picture
News

Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor

SAN DIEGO, Jan. 15, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, announced today that it has dosed the first patient in a Phase 1/2 clinical trial of MRTX849, an investigational KRAS G12C… […]

No Picture
News

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2018 Financial Results

Conference Call and Webcast Scheduled for Tuesday, February 5

SAN DIEGO, Jan. 15, 2019 /PRNewswire/ — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2018 financial results after the Nasdaq… […]

No Picture
News

GenScript Launches Novel Technology Licensed from Amgen for Accelerating Protein and Antibody Purification

AmMag SA magnetic purification system first to offer high throughput of large samples, accelerating early stage drug development

SAN DIEGO, Jan. 14, 2019 /PRNewswire/ — GenScript®, the world’s leading gene synthesis provider, announced today at PepT… […]

No Picture
News

Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference

– Anticipated ENHANZE® Partner Progress in 2019 Includes One FDA Approval, New Regulatory Submissions and a New Phase 3 Initiation- Completed Enrollment in Phase 3 Metastatic Pancreas Cancer Study with Data Projected in Second Half of 2019

SAN DIEGO,… […]

No Picture
News

In Promise of True Liquid Biopsy for Cancer, Chip Company BioFluidica® Awarded $1.7 Million by National Cancer Institute/National Institutes of Health for Clinical Trial in Children with Acute Lymphoblastic Leukemia

SAN DIEGO, Jan. 7, 2019 /PRNewswire/ — BioFluidica, a privately held cancer diagnostics company, has been awarded an SBIR Phase II National Institutes of Health grant of $1.7 million for a clinical trial in support of “Increased sensitivity of mini… […]